235 related articles for article (PubMed ID: 30359253)
21. Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity?
Borde C; Kand P; Basu S
World J Radiol; 2012 May; 4(5):220-3. PubMed ID: 22761982
[TBL] [Abstract][Full Text] [Related]
22. Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis.
Osborne MT; Hulten EA; Singh A; Waller AH; Bittencourt MS; Stewart GC; Hainer J; Murthy VL; Skali H; Dorbala S; Di Carli MF; Blankstein R
J Nucl Cardiol; 2014 Feb; 21(1):166-74. PubMed ID: 24307261
[TBL] [Abstract][Full Text] [Related]
23. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
24. Radionuclide ventriculography detects early anthracycline cardiotoxicity in children with Hodgkin lymphoma.
Tantawy AA; Elmasry OA; Shaaban M; Toaima DN; El Shahat AM
J Pediatr Hematol Oncol; 2011 May; 33(4):e132-7. PubMed ID: 21516011
[TBL] [Abstract][Full Text] [Related]
25. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
[TBL] [Abstract][Full Text] [Related]
26. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
27. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process.
Paraskevaidis IA; Makavos G; Tsirigotis P; Psarogiannakopoulos P; Parissis J; Gkirkas K; Pessach I; Ikonomidis I
J Am Soc Echocardiogr; 2017 Nov; 30(11):1091-1102. PubMed ID: 28864152
[TBL] [Abstract][Full Text] [Related]
28. Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis.
Bax JJ; Schinkel AF; Boersma E; Elhendy A; Rizzello V; Maat A; Roelandt JR; van der Wall EE; Poldermans D
Circulation; 2004 Sep; 110(11 Suppl 1):II18-22. PubMed ID: 15364832
[TBL] [Abstract][Full Text] [Related]
29. Relationship between mechanical and metabolic dyssynchrony with left bundle branch block: evaluation by 18-fluorodeoxyglucose positron emission tomography in patients with non-ischemic heart failure.
Castro P; Winter JL; Verdejo H; Orellana P; Quintana JC; Greig D; Enríquez A; Sepúlveda L; Concepción R; Sepúlveda P; Rossel V; Chiong M; García L; Lavandero S
J Heart Lung Transplant; 2012 Oct; 31(10):1096-101. PubMed ID: 22975099
[TBL] [Abstract][Full Text] [Related]
30. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
31. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
32. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
33. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy.
Sipola P; Vanninen E; Jantunen E; Nousiainen T; Kiviniemi M; Hartikainen J; Kuittinen T
Nucl Med Commun; 2012 Jan; 33(1):51-9. PubMed ID: 22044862
[TBL] [Abstract][Full Text] [Related]
34. Shifts in myocardial fatty acid and glucose metabolism in pulmonary arterial hypertension: a potential mechanism for a maladaptive right ventricular response.
Ohira H; deKemp R; Pena E; Davies RA; Stewart DJ; Chandy G; Contreras-Dominguez V; Dennie C; Mc Ardle B; Mc Klein R; Renaud JM; DaSilva JN; Pugliese C; Dunne R; Beanlands R; Mielniczuk LM
Eur Heart J Cardiovasc Imaging; 2016 Dec; 17(12):1424-1431. PubMed ID: 26060207
[TBL] [Abstract][Full Text] [Related]
35. Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy.
Vera T; D'Agostino RB; Jordan JH; Whitlock MC; Meléndez GC; Lamar ZS; Porosnicu M; Bonkovsky HL; Poole LB; Hundley WG
Am J Cardiol; 2015 Dec; 116(11):1752-5. PubMed ID: 26433273
[TBL] [Abstract][Full Text] [Related]
36. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
37. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.
Murtagh G; Lyons T; O'Connell E; Ballot J; Geraghty L; Fennelly D; Gullo G; Ledwidge M; Crown J; Gallagher J; Watson C; McDonald KM; Walshe JM
Breast Cancer Res Treat; 2016 Apr; 156(3):501-506. PubMed ID: 27060913
[TBL] [Abstract][Full Text] [Related]
38. Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy.
Nousiainen T; Vanninen E; Jantunen E; Puustinen J; Remes J; Rantala A; Hartikainen J
J Intern Med; 2001 Apr; 249(4):297-303. PubMed ID: 11298849
[TBL] [Abstract][Full Text] [Related]
39. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
40. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
